Response to lorlatinib rechallenge in a case of ALK-rearranged metastatic NSCLC with a resistance mutation to second generation TKIs.
Rita LeporatiDaniela MilizianoTeresa BeninatoLaura MazzeoSara ManglavitiMarta BrambillaMario Alberto OcchipintiArsela PrelajClaudia ProtoGiuseppe Lo RussoPublished in: Tumori (2024)
In this case, the first ALK resistance mutation detected after progression on first line TKI, the I1171N, is a common resistance mutation after alectinib and confers sensitivity to brigatinib, that the patient received afterwards with a long-term disease stability. The second ALK resistance mutation detected after a chemotherapy interval, the G1202R, is the most common resistance mutation after second generation ALK TKIs and has been associated with sensitivity to third generation TKIs, such as lorlatinib. This case of a patient with EML4-ALK-rearranged NSCLC shows that sequential treatment with next-generation ALK TKIs, including rechallenge, can induce profound remissions, even in heavily pretreated patients, and that ALK-targeted strategies may be personalized by considering the presence of distinct ALK resistance mutations.
Keyphrases
- advanced non small cell lung cancer
- small cell lung cancer
- epidermal growth factor receptor
- end stage renal disease
- chronic kidney disease
- ejection fraction
- case report
- drug delivery
- autism spectrum disorder
- intellectual disability
- cancer therapy
- radiation therapy
- prognostic factors
- patient reported outcomes
- peritoneal dialysis